|
OUR PRODUCT PIPELINE
The following table summarizes certain of our product candidates currently in development either by us or through our sub-licensees:
| Product |
Indication(s) |
Status |
Marketing
Rights |
| Indiplon |
Insomnia |
Registration(1) |
Neurocrine |
| Bicifadine |
Pain |
Phase
II/III(2) |
XTL |
| DOV
21,947 |
Depression
Obesity |
Phase II planned for 2007
Preclinical |
DOV
DOV |
| DOV
102,677 |
Alcohol
Abuse/Alcoholism |
Phase
Ib contemplated(3) |
DOV |
| Triple reuptake inhibitor |
Depression |
Pre-IND(4) |
DOV |
|
(1) Neurocrine has stated that it plans to resubmit its NDA for indiplon capsules by the end of the second quarter of 2007.
(2) Our partner, XTL, has stated that it intends to initiate a Phase IIb clinical trial in neuropathic pain in 2007 with bicifadine. Bicifadine has been studied in five Phase III clinical trials.
(3) We may initiate a Phase I clinical trial in normal volunteers for DOV 102,677 to support subsequent studies in the alcohol abuse indication in late 2007 if appropriate funding is available.
(4) We intend to select a triple reuptake inhibitor development candidate from our preclinical pipeline in 2007 and file an IND for the selected compound with the FDA in early 2008.
|